Shire plc, a biotechnology company, researches, develops, licenses, manufactures, markets, distributes, and sells medicines for rare diseases and other specialized conditions worldwide. The company offers products in therapeutic areas, including hematology, genetic diseases, neuroscience, immunology, internal medicine, ophthalmology, and oncology. Its marketed products include ADVATE, ADYNOVATE/ADYNOVI, and OBIZUR for the treatment of hemophilia A; RIXUBIS to treat hemophilia B; VONVENDI for the treatment of von willebrand disease; FEIBA to treat hemophilia A and B patients with inhibitors; ELAPRASE to treat hunter syndrome; REPLAGAL for fabry disease; and VPRIV to treat type 1 Gaucher disease.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone353-1609-6000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$15.16 billion
Profitability
Miscellaneous
EmployeesN/A
Next Earnings DateN/A
OptionableOptionable
Shire (NASDAQ:SHPG) Frequently Asked Questions
What is Shire's stock symbol?
Shire trades on the NASDAQ under the ticker symbol "SHPG."
How were Shire's earnings last quarter?
Shire PLC (NASDAQ:SHPG) announced its earnings results on Thursday, April, 26th. The biopharmaceutical company reported $3.86 EPS for the quarter, beating analysts' consensus estimates of $3.58 by $0.28. The biopharmaceutical company had revenue of $3.77 billion for the quarter. Shire had a net margin of 30.63% and a return on equity of 12.70%. The business's revenue was up 5.4% compared to the same quarter last year. During the same period in the previous year, the firm earned $3.63 earnings per share. View Shire's Earnings History.
What price target have analysts set for SHPG?
4 brokers have issued 12 month price targets for Shire's shares. Their forecasts range from $222.00 to $222.00. On average, they expect Shire's share price to reach $222.00 in the next year. View Analyst Price Targets for Shire.
What is the consensus analysts' recommendation for Shire?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Shire in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Shire.
Has Shire been receiving favorable news coverage?
Media coverage about SHPG stock has been trending positive recently, according to InfoTrie Sentiment. InfoTrie rates the sentiment of press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Shire earned a news impact score of 3.0 on InfoTrie's scale. They also gave news coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the company's share price in the near future. View News Stories for Shire.
Who are some of Shire's key competitors?
Some companies that are related to Shire include Merck & Co., Inc. (MRK), Novartis (NVS), Pfizer (PFE), Abbott Laboratories (ABT), Novo Nordisk A/S (NVO), AbbVie (ABBV), AstraZeneca (AZN), Sanofi (SNY), GlaxoSmithKline (GSK), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), Commonwealth Bank of Australia (CSLLY), Celgene (CELG), Bayer (BAYRY) and Takeda Pharmaceutical (TAK).
What other stocks do shareholders of Shire own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Shire investors own include Gilead Sciences (GILD), Celgene (CELG), Intel (INTC), Merck & Co., Inc. (MRK), Cisco Systems (CSCO), Walt Disney (DIS), Starbucks (SBUX), Johnson & Johnson (JNJ), Pfizer (PFE) and Exxon Mobil (XOM).
Who are Shire's key executives?
Shire's management team includes the folowing people:
- Dr. Flemming Ornskov M.P.H., MBA, M.D., MPH, CEO, MD & Exec. Director (Age 60)
- Mr. Thomas J. W. Dittrich, CFO & Director (Age 54)
- Gisele Dion, Chief Accounting Officer
- Mr. Matthew Walker, Head of Technical Operations (Age 54)
- Dr. Andreas Busch Ph.D., Head of R&D and Chief Scientific Officer (Age 55)
How big of a company is Shire?
Shire has a market capitalization of $0.00 and generates $15.16 billion in revenue each year. The biopharmaceutical company earns $4.27 billion in net income (profit) each year or $15.15 on an earnings per share basis. View Additional Information About Shire.
What is Shire's official website?
How can I contact Shire?
Shire's mailing address is BLOCK 2 MIESIAN PLAZA 50-58 BAGGOT STREET LOWER, Dublin L2, D02. The biopharmaceutical company can be reached via phone at 353-1609-6000 or via email at [email protected]
MarketBeat Community Rating for Shire (NASDAQ SHPG)
MarketBeat's community ratings are surveys of what our community members think about Shire and other stocks. Vote "Outperform" if you believe SHPG will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SHPG will underperform the S&P 500 over the long term. You may vote once every thirty days.
